C
아미코젠
092040KOSDAQ42.0 / 100
Reference Date: 2026-10-23
Financial Score14.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure7.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Rose 9.4% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Amicozen is an industrial biotech company specializing in developing enzymes for antibiotic production and health care materials using its proprietary gene evolution technology. Key products include N-acetylglucosamine, phytin, and collagen peptides, with expansion into endolysin enzyme business through collaboration with Lysando AG since 2020.
Number of Employees
228people
Average Salary
49.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.71Industry Average 1.205.5Point
Lower than industry avg (good)
ROE
-27.74Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
57.69Industry Average 100.005.0Point
Lower than industry avg (good)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼33.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼293.0% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -22.7% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (5%, downtrend)
Current 965Won52-week high 3,31552-week low 839
1-month return5.0Point
1m +9.41% (rising)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
4 totalPositive 0Neutral 3Negative 1
- Neutral[기재정정]반기보고서 (2026.06)2026-10-12
- Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-10-12
- Neutral[기재정정]주주명부폐쇄기간또는기준일설정2026-10-12
- Negative불성실공시법인지정 (공시번복 2건)2026-09-28